EOEric Olsson

Eric Olsson

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Eric Olsson has a total of 54 co-authors. Here are the top co-authors by number of shared publications:

  • Urban Ösby

    Center for Molecular Medicine, Karolinska University Hospital Solna, Stockholm, Sweden; Department of Adult Psychiatry, PRIMA Barn och Vuxenpsykiatri AB, Stockholm, Sweden; Centre for Family Medicine, Department of Neurobiology, Care Sciences and Society, Karolinska Institutet, Stockholm, Sweden

    4 shared publications
  • Gunnar Edman

    Department of Neurobiology , Care Sciences and Society, Centre of Family Medicine, Karolinska Institutet , Stockholm , Sweden ; Center for Molecular Medicine , Karolinska University Hospital , Stockholm , Sweden ; Department of Psychiatry , Tiohundra AB , Norrtälje , Sweden

    3 shared publications
  • Sven Vilhelm Eriksson

    Department of Medicine, Danderyds Hospital, Stockholm, Sweden

    3 shared publications
  • Agneta Hilding

    Department of Molecular Medicine and Surgery , Karolinska Institutet , Stockholm , Sweden

    2 shared publications
  • Catharina Lavebratt

    Neurogenetics Unit, Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden; Center for Molecular Medicine, Karolinska University Hospital Solna, Stockholm, Sweden

    2 shared publications
  • Claes-Göran Östenson

    Endocrine and Diabetes Unit, Department of Molecular Medicine and Surgery; Karolinska Institutet, Stockholm, Sweden

    2 shared publications

Latest Publications

  • Open Access

    POS0549 BREAKTHROUGH SARS-COV-2 INFECTION IN FULLY VACCINATED PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS FROM THE COVID-19 VACCINATION IN AUTOIMMUNE DISEASE (COVAD) STUDY

    by E. Kihlgren Olsson, N. Ravichandran, E. Nikiphorou, J. Lindblom, S. Saha, S. S. Shaharir, W. Katchamart, P. A. Goo, L. Traboco, Y. M. Chen, et al.

    Background Although many studies have been conducted on COVID-19 in recent years, there are still unanswered questions regarding breakthrough infections (BTIs), particularly in patients with systemic lupus erythematosus (SLE). Objectives This study aimed to determine the occurrence of breakthrough COVID-19 infections in patients with SLE versus other autoimmune rheumatic diseases (AIRDs), non-rheumatic autoimmune diseases (nrAIDs), and healthy controls (HCs). Methods The study was based on data from the COVAD questionnaire which amassed a total of 10,783 complete responses from patients with SLE, AIRD, or nrAIRD, and HCs. After exclusion of individuals who were unvaccinated, those who received one vaccine dose only, and those with uncertain responses regarding the vaccine doses, a total of 9,595 patients formed the study population of the present investigation. If a COVID-19 infection occurred after the initial two vaccine doses and at least one booster dose (at least three doses in total, herein termed full vaccination), it was considered a BTI. Data were analysed using multivariable regression models. Statistically significant results were denoted by p values Results A total of 7,016/9,595 (73.1%) individuals were fully vaccinated. Among those, 1,002 (14.2%) reported at least one BTI, and 166 (2.3%) reported at least two BTIs. Among SLE patients, 867/1,218 (71.2%) were fully vaccinated. Among fully vaccinated SLE patients, 137 (15.8%) reported at least one BTI while 28 (3.2%) reported at least two BTIs. BTI frequencies in fully vaccinated SLE patients were comparable to those of other AIRDs (OR: 1.0; 95% CI: 0.8–1.3; p=0.447) and nrAIDS (OR: 0.9; 95% CI: 0.6–1.3; p=0.856) but higher compared with HCs (OR: 1.2; 95% CI: 1.0–1.6; p=0.022). For SLE patients with three vaccine doses, 113/137 (82.5%) reported at least one BTI while the corresponding number for four vaccine doses was 24/137 (17.5%). Compared with HCs (OR: 10.6; 95% CI: 1.2–93.0; p=0.032) and other AIRDs (OR: 3.5; 95% CI: 1.08–11.5; p=0.036), SLE patients showed higher frequencies of hospitalisation. AID multimorbidity was associated with a 15-fold increased risk for a need of advanced treatment for COVID-19 (OR: 15.3; 95% CI: 2.6–88.2; p=0.002). Conclusion COVID-19 BTIs occurred in nearly 1 every 6th fully vaccinated patient with SLE, and 20% more frequently in this patient population compared with fully vaccinated HCs. Moreover, BTIs in SLE patients were more severe compared with BTIs in HCs or patients with AIRDs other than SLE, resulting in a greater need for hospitalisation. AID multimorbidity contributed to a more severe COVID-19 BTI requiring advanced management. These insights call for greater attention to vaccination in the vulnerable group of SLE patients, with appropriate risk stratification towards optimised vaccination strategies. Survival analysis across patients with SLE, AIRDs, or nrAIDs, and HCs. SLE: systemic lupus erythematosus; AIRD: autoimmune rheumatic disease; nrAID: non-rheumatic autoimmune disease; HC: healthy control. Acknowledgements The authors thank all survey respondents, as well as patient associations and all members of the COVAD study group for their invaluable role in the data collection. Disclosure of Interests Emelie Kihlgren Olsson: None declared, Naveen Ravichandran: None declared, Elena Nikiphorou Speakers bureau: EN has received speaker honoraria/participated in advisory boards for Celltrion, Pfizer, Sanofi, Gilead, Galapagos, AbbVie, and Lilly., Consultant of: EN has received speaker honoraria/participated in advisory boards for Celltrion, Pfizer, Sanofi, Gilead, Galapagos, AbbVie, and Lilly., Grant/research support from: EN holds research grants from Pfizer and Lilly., Julius Lindblom: None declared, Sreoshy Saha: None declared, Syahrul Sazliyana Shaharir: None declared, Wanruchada Katchamart: None declared, Phonpen Akarawatcharangura Goo: None declared, Lisa Traboco: None declared, Yi-Ming Chen: None declared, Kshitij Jagtap: None declared, James B. Lilleker Speakers bureau: JBL has received speaker honoraria for Sanofi Genzyme, Roche, and Biogen. None is related to this manuscript. Consultant of: JBL has participated in advisory boards for Sanofi Genzyme, Roche, and Biogen. None is related to this manuscript. Arvind Nune: None declared, John Pauling: None declared, Chris Wincup: None declared, Vishwesh Agarwal: None declared, Dey Dzifa: None declared, Carlos Enrique Toro Gutierrez: None declared, Carlo Vinicio Caballero: None declared, Hector Chinoy Speakers bureau: HC has been a speaker for UCB, and Biogen., Consultant of: HC has received consulting fees from Novartis, Eli Lilly, Orphazyme, Astra Zeneca., Grant/research support from: HC was supported by the National Institution for Health Research Manchester Biomedical Research Centre Funding Scheme. The views expressed in this publication are those of the authors and not necessarily those of the NHS, National Institute for Health Research, or Department of Health. HC has received grant support from Eli Lilly and UCB., Vikas Agarwal: None declared, Rohit Aggarwal Consultant of: RA has a consultancy relationship with and/or has received research funding from the following companies: Bristol Myers-Squibb, Pfizer, Genentech, Octapharma, CSL Behring, Mallinckrodt, AstraZeneca, Corbus, Kezar, Abbvie, Janssen, Kyverna Alexion, Argenx, Q32, EMD-Serono, Boehringer Ingelheim, Roivant, Merck, Galapagos, Actigraph, Scipher, Horizon Therapeutics, Teva, Beigene, ANI Pharmaceuticals, Biogen, Nuvig, Capella Bioscience, and CabalettaBio., Grant/research support from: RA has a consultancy relationship with and/or has received research funding from the following companies: Bristol Myers-Squibb, Pfizer, Genentech, Octapharma, CSL Behring, Mallinckrodt, AstraZeneca, Corbus, Kezar, Abbvie, Janssen, Kyverna Alexion, Argenx, Q32, EMD-Serono, Boehringer Ingelheim, Roivant, Merck, Galapagos, Actigraph, Scipher, Horizon Therapeutics, Teva, Beigene, ANI Pharmaceuticals, Biogen, Nuvig, Capella Bioscience, and CabalettaBio., Latika Gupta: None declared, Ioannis Parodis Grant/research support from: IP has received research funding and/or honoraria from Amgen, AstraZeneca, Aurinia Pharmaceuticals, Elli Lilly and Company, Gilead Sciences, GlaxoSmithKline, Janssen Pharmaceuticals, Novartis and F. Hoffmann-La Roche AG.

  • Troponin T levels associated with genetic variants in NOTCH2 and MTNR1B in women with psychosis

    by Dzana Sudic Hukic, Catharina Lavebratt, Eric Olsson, Claes-Göran Östenson, Sven V. Eriksson, David Erlinge, Martin Schalling, Urban Ösby


  • Open Access

    Diabetes and glucose disturbances in patients with psychosis in Sweden

    by Eric Olsson, Jeanette Westman, Dzana Sudic Hukic, Sven V Eriksson, Gunnar Edman, Robert Bodén, Erik Jedenius, Johan Reutfors, Anders Berntsson, Agneta Hilding, et al.

    Objective: The objectives of this study were to (1) analyze the prevalence of diabetes, prediabetes, and antidiabetic medication in patients with psychosis compared with control subjects and (2) determine what factors in patients with psychosis were associated with antidiabetic medication. Method: We studied 977 patients with psychosis recruited from outpatient clinics in Stockholm County, Sweden, and they were compared with 3908 non-psychotic control subjects for fasting plasma glucose levels; prevalence of diabetes, prediabetes, antidiabetic treatment, and tobacco use; and blood pressure, weight, height, and waist circumference. Group differences were evaluated with analysis of variance and χ2 test, and factors associated with antidiabetic treatment were evaluated with logistic regression. Results: Diabetes was observed in 94 (10%) patients with psychosis, 2.7 times the prevalence observed in control subjects. Among patients with psychosis, 87 (10%) had prediabetes (fasting glucose, 6.1–6.9 mmol/L) compared with 149 (3.8%) control subjects. Most patients with psychosis (77%) who had prediabetes fulfilled criteria for metabolic syndrome. In patients with psychosis, both lipid-lowering medication and fasting glucose were significantly associated with antidiabetic treatment. There was no significant relation between antidiabetic treatment and lifestyle factors such as smoking or degree of psychiatric illness. Conclusions: The high prevalence of impaired fasting glucose and metabolic syndrome in patients with psychosis warrants further clinical research in preventing or delaying the onset of diabetes in these patients by pharmacotherapy and/or lifestyle intervention.


  • Genetic and Clinical Factors Affecting Plasma Clozapine Concentration

    by Eric Olsson, Gunnar Edman, Leif Bertilsson, Dzana Sudic Hukic, Catharina Lavebratt, Sven V. Eriksson, Urban Ösby

    To assess (1) the variance of plasma clozapine levels; (2) the relative importance of sex, smoking habits, weight, age, and specific genetic variants of cytochrome P450 1A2 (CYP1A2), uridine diphosphate glucuronosyltransferase 1A4 (UGT1A4), and multidrug resistance protein 1 (MDR1) on plasma levels of clozapine; and (3) the relation between plasma clozapine levels, fasting glucose levels, and waist circumference. There were 113 patients on clozapine treatment recruited from psychosis outpatient clinics in Stockholm County, Sweden. Patients had genotype testing for single nucleotide polymorphisms: 2 in MDR1, 3 in CYP1A2, and 1 in UGT1A4. Multiple and logistic regression were used to analyze the relations. There was a wide variation in plasma concentrations of clozapine (mean = 1,615 nmol/L, SD = 1,354 nmol/L), with 37% of the samples within therapeutic range (1,100-2,100 nmol/L). Smokers had significantly lower plasma clozapine concentrations than nonsmokers (P ≤ .03). There was a significant association between the rs762551 A allele of CYP1A2 and lower plasma clozapine concentration (P ≤ .05). Increased fasting glucose level was 3.7-fold more frequent in CC and CA genotypes than AA genotype (odds ratio = 0.27; 95% confidence interval, 0.10-0.72). There was no significant relation between higher fasting glucose levels, larger waist circumference, and higher clozapine levels. It is difficult to predict plasma clozapine concentration, even when known individual and genetic factors are considered. Therefore, therapeutic drug monitoring is recommended in patients who are treated with clozapine.


  • Psychotic disorder is an independent risk factor for increased fasting glucose and waist circumference

    by Urban Ösby, Eric Olsson, Gunnar Edman, Agneta Hilding, Sven V. Eriksson, Claes Göran Östenson

    Background. Psychosis is associated with excess cardiovascular morbidity and mortality. Aims. To determine the prevalence of cardiovascular risk factors in patients with psychotic disorders compared with the population. Methods. 731 consecutive patients with psychosis recruited from psychiatric outpatient clinics in Stockholm County, Sweden, were compared with 5580 individuals from a population study performed in the same area. The main outcome measures were waist circumference, body mass index (BMI) and fasting glucose. Results. Mean waist circumference in patients vs. controls was for males 106 and 94 cm, respectively, and for females 97 and 85 cm, respectively (P < 0.001); mean fasting glucose in patients vs. controls was for males 5.8 and 5.2 mmol/l, respectively, and for females 5.6 and 4.8 mmol/l, respectively (P < 0.001). Comparisons were controlled for differences in age and family history of diabetes. Increased waist circumference was more common in psychotic patients compared with controls (OR = 3.99; 95% CI 3.09–5.15), controlling for fasting insulin, differences in gender, blood pressure, fasting glucose, family history of diabetes, age and tobacco use. Increased fasting blood glucose was also more common in psychotic patients (OR = 2.41; 95% CI 1.84–3.14) controlling for the same factors with the exception of fasting glucose and with the addition of increased waist circumference. Conclusion. Our study shows that the psychosis illness per se can be considered as a cardiovascular risk factor, independent of the traditional risk factors such as age and smoking.


  • Poster #98 VALIDATION OF SUICIDE AS CAUSE OF DEATH IN CASES OF UNDETERMINED MANNER OF DEATH IN SCHIZOPHRENIA IN SWEDEN

    by Eric M. Olsson, Diana Hukic, Lise-Lotte Nilsson, Henrik Druid, Martin Schalling, Urban Ösby

  • Cellular localization of three vesicular glutamate transporter mRNAs and proteins in rat spinal cord and dorsal root ganglia

    by Alexandre L.R. Oliveira, Fredrik Hydling, Eric Olsson, Tiejun Shi, Robert H. Edwards, Fumino Fujiyama, Takeshi Kaneko, Tomas Hökfelt, Staffan Cullheim, Björn Meister

    Glutamate is transported into synaptic vesicles by vesicular glutamate transporter (VGLUT) proteins. Three different VGLUTs, VGLUT1, VGLUT2, and VGLUT3, have recently been characterized, and they are considered to represent the most specific marker so far for neurons using glutamate as transmitter. We analyzed the cellular localization of VGLUT1‐3 in the rat spinal cord and dorsal root ganglia (DRGs) in control rats and after dorsal rhizotomy. Using in situ hybridization, VGLUT1 mRNA containing neurons were shown in the dorsomedial part of the intermediate zone, whereas VGLUT2 mRNA‐expressing neurons were present in the entire intermediate zone, both populations most likely representing interneurons. VGLUT3 mRNA could not be detected in the spinal cord. In the ventral horn, a dense plexus of VGLUT1‐immunoreactive (ir) nerve terminals was present, with large varicosities abutting on presumed motoneurons. In the dorsal horn a similarly dense plexus was seen, except in laminae I and II. A very dense plexus of VGLUT2‐ir fibers was distributed in the entire gray matter of the spinal cord, with many fibers lying close to presumed motoneurons. Few VGLUT3‐ir fibers were distributed in the white and gray matter, including lamina IX. However, a dense VGLUT3‐ir plexus was seen in the sympathetic intermedio‐lateral column (IML). Multiple‐labeling immunohistochemistry revealed that the VGLUT1‐, VGLUT2‐, and VAChT‐containing varicosities in lamina IX all represent separate entities. There was no colocalization of VGLUT3 with VAChT or 5‐HT in varicose fibers of the ventral horn, but some VGLUT3‐ir fibers in the IML were 5‐HT‐positive. Lesioning of the dorsal roots resulted in an almost complete disappearance of VGLUT1‐ir fibers around motoneurons and a less pronounced decrease in the remaining gray matter, whereas the density of VGLUT2‐ and VAChT‐ir fibers appeared unaltered after lesion. Many VGLUT1‐ir neurons were observed in DRGs; they were almost all large and did not colocalize calcitonin gene‐related peptide (CGRP), and there was no overlap between these markers in fibers in the superficial dorsal horn. VGLUT2 was, at most, seen in a few DRG neurons. Taken together, these results suggest that the VGLUTs mRNAs are present in distinct subsets of neuronal populations at the spinal level. VGLUT1 is mainly present in primary afferents from large, CGRP‐negative DRG neurons, VGLUT2 has mainly a local origin, and VGLUT3 fibers probably have a supraspinal origin. Synapse 50:117–129, 2003.